DMAC יחס שווי שוק לשווי בספרים diamedica.com

The historical price action of DiaMedica Therapeutics (DMAC) is recorded at 13.86. DiaMedica Therapeutics is implementing robotics into the synthesis of kidney therapy agents, although final tests remain the responsibility of physicians. Additionally, the business is developing DM199 to restore cerebral blood flow following strokes. However, a narrow development profile lacking a broad product portfolio creates a critical dependency on the outcomes of clinical trials.

This indicator determines the market revaluation coefficient of net assets, comparing the current share price with book value to identify the degree of speculative overvaluation or undervaluation of the business. Analyzing changes in the revaluation level of book capital allows for an assessment of the investment attractiveness of DiaMedica Therapeutics (DMAC), given the high cost of specialized developments in the therapy of renal pathologies and stroke.